Japan's Ministry of Health, Labour and Welfare Approves GSK's Arexvy, the Country's First Respiratory Syncytial Virus Vaccine for Older Adults
September 26, 2023
September 26, 2023
LONDON, England, Sept. 26 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on Sept. 25, 2023:
GSK plc (LSE/NYSE: GSK) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) for the prevention of RSV (respiratory syncytial virus) disease for adults 60 years of age and above. This is the first time an RSV vaccine for older adults has been approve . . .
GSK plc (LSE/NYSE: GSK) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) for the prevention of RSV (respiratory syncytial virus) disease for adults 60 years of age and above. This is the first time an RSV vaccine for older adults has been approve . . .